EUVIMEDEUVIMED entdecken
Kohortenstudie

The Upgrade Risk of B3 Lesions to (Pre)Invasive Breast Cancer After Diagnosis on Core Needle or Vacuum Assisted Biopsy. A Belgian National Cohort Study

Nynke Willers, Patrick Neven, Giuseppe Floris, Cecile Colpaert, Eva Oldenburger, Sileny Han, Chantal Van Ongeval, Ann Smeets, Francois P Duhoux, Hans Wildiers, Petra Denolf, Nele Laudus und 4 weitere

Clinical Breast Cancer · 2023-06 · 23 (4) · e273-e280

DOI: 10.1016/j.clbc.2023.03.006 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Breast Cancer, 2023-06. Verfasst von Nynke Willers und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, KU Leuven - University of Leuven, Leuven, Belgium; Department of Senology, AZ Sint Blasius, Dendermonde, Belgium. Electronic …. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Breakthrough Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Flat epithelial atypia (FEA), lobular neoplasia (LN), papillary lesions (PL), radial scar (RS) and atypical ductal hyperplasia (ADH) are lesions of uncertain malignant potential and classified as B3 lesions by the European guidelines for quality assurance in breast cancer screening and diagnosis. Current management is usually wide local excision (WE), surveillance may be sufficient for some. We investigated the upgrade rate of B3 lesions to breast malignancy in a subsequent resection specimen after diagnosis on core needle-or vacuum assisted biopsy (CNB-VAB) in a national population-based series. METHODS: Using data from the Belgian Cancer Registry (BCR) between January 1, 2013 and December 31, 2016, inclusion criteria were new diagnosis of a B3 lesion on CNB or VAB with subsequent histological assessment on a wider excision specimen. Histological agreement between first- and follow-up investigation was analyzed to determine the upgrade risk to ductal adenocarcinoma in situ (DCIS) or invasive breast cancer (IC) according to the type of B3 lesion. RESULTS: Of 1855 diagnosed B3 lesions, 812 were included in this study: 551 after CNB-261 after VAB. After diagnosis on CNB and VAB, we found 19.0% and 14.9% upgrade to malignancy respectively. Upgrade risks after CNB and VAB were: FEA 39.5% and 17.6%; LN 40.5% and 4.3%; PL 10.4% and 12.5%; RS 25.7%and 0.0%; ADH 29.5% and 20.0%. CONCLUSION: Based on the observed upgrade rate we propose three recommendations: first, resection of ADH, and FEA with WE; second, resection of RS and classical LN with therapeutic VAB and further surveillance when radio-pathological correlation is concordant; third, surveillance of PL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCarcinoma, Intraductal, NoninfiltratingFibrocystic Breast DiseaseFemaleHumansCohort StudiesBelgiumMammographyBiopsy, Large-Core NeedleBreastRetrospective Studies

Stichwörter der Autor:innen

B3 lesionBreastDuctal carcinoma in situInvasive carcinomaUpgrade

Autor:innen und Institutionen

  • Department of Oncology, KU Leuven - University of Leuven, Leuven, Belgium; Department of Senology, AZ Sint Blasius, Dendermonde, Belgium. Electronic address: nynke.willers@uzleuven.be.
  • Department of Oncology, KU Leuven - University of Leuven, Leuven, Belgium; Department of Gynecological Oncology, University Hospitals Leuven, Leuven, Belgium.
  • Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research, KU Leuven - University of Leuven, Leuven, Belgium; Department of Pathology, University Hospitals Leuven, Leuven, Belgium.
  • Department of Pathology, University Hospitals Leuven, Leuven, Belgium; Research Department, Belgian Cancer Registry, Brussels, Belgium.
  • Department of Oncology, KU Leuven - University of Leuven, Leuven, Belgium; Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.
  • Department of Oncology, KU Leuven - University of Leuven, Leuven, Belgium; Department of Radiology, University Hospitals Leuven, Leuven, Belgium.

Förderung

  • Breakthrough Cancer Research

Zitieren

APA

Willers, N., Neven, P., Floris, G., Colpaert, C., Oldenburger, E., Han, S., Van Ongeval, C., Smeets, A., Duhoux, F. P., Wildiers, H., Denolf, P., Laudus, N., Dequeker, E., De Brabander, I., Van Damme, N., & De Schutter, H. (2023). The Upgrade Risk of B3 Lesions to (Pre)Invasive Breast Cancer After Diagnosis on Core Needle or Vacuum Assisted Biopsy. A Belgian National Cohort Study. Clinical Breast Cancer, 23(4), e273-e280. https://doi.org/10.1016/j.clbc.2023.03.006

Vancouver

Willers N, Neven P, Floris G, Colpaert C, Oldenburger E, Han S, et al. The Upgrade Risk of B3 Lesions to (Pre)Invasive Breast Cancer After Diagnosis on Core Needle or Vacuum Assisted Biopsy. A Belgian National Cohort Study. Clinical Breast Cancer. 2023;23(4):e273-e280. doi:10.1016/j.clbc.2023.03.006

BibTeX
@article{Willers2023,
  author = {Willers, Nynke and Neven, Patrick and Floris, Giuseppe and Colpaert, Cecile and Oldenburger, Eva and Han, Sileny and Van Ongeval, Chantal and Smeets, Ann and Duhoux, Francois P and Wildiers, Hans and Denolf, Petra and Laudus, Nele and Dequeker, Els and De Brabander, Isabel and Van Damme, Nancy and De Schutter, Harlinde},
  title = {The Upgrade Risk of B3 Lesions to (Pre)Invasive Breast Cancer After Diagnosis on Core Needle or Vacuum Assisted Biopsy. A Belgian National Cohort Study},
  journal = {Clinical Breast Cancer},
  year = {2023},
  volume = {23},
  number = {4},
  pages = {e273--e280},
  doi = {10.1016/j.clbc.2023.03.006}
}
Kostenlos starten →